Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection (C/SOAP)

This study is currently recruiting participants.
Verified March 2012 by University of Alabama at Birmingham
Sponsor:
Collaborators:
University of Texas
University of North Carolina
Information provided by (Responsible Party):
Alan Tita, University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT01235546
First received: November 4, 2010
Last updated: March 27, 2012
Last verified: March 2012
  Purpose

The Cesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) study is a large pragmatic multi-center randomized clinical trial designed to evaluate the comparative effectiveness and safety of azithromycin-based extended-spectrum antibiotic prophylaxis (azithromycin plus standard narrow-spectrum cephalosporin) relative to standard single-agent cephalosporin prior to surgical incision to prevent post-cesarean infection.

Hypothesis: Compared to narrow-spectrum prophylaxis (i.e. cefazolin alone, or clindamycin if cephalosporin allergy) prior to surgical incision, the addition of extended-spectrum prophylaxis (azithromycin + cefazolin) reduces the incidence of post-cesarean infection.


Condition Intervention
Endometritis
Wound Infection
Abscess
Surgical Site Infection
Drug: Azithromycin
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Cesarean Section Optimal Antibiotic Prophylaxis Trial

Resource links provided by NLM:


Further study details as provided by University of Alabama at Birmingham:

Primary Outcome Measures:
  • Composite of endometritis and/or wound infection and/or other post-cesarean infections (occurring within 4 weeks of delivery) [ Time Frame: 4 weeks after delivery ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • • Individual post-cesarean infections: Endometritis, wound infection (including necrotizing fascitis), other infections including abscess, septic thrombosis, pneumonia, pyelonephritis and breast infection [ Time Frame: 4 weeks after delivery ] [ Designated as safety issue: No ]

Estimated Enrollment: 2000
Study Start Date: May 2011
Estimated Study Completion Date: July 2014
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
250 cc normal saline
Drug: Placebo
250 cc normal saline
Experimental: Azithromycin Drug: Azithromycin
500 mg in 250 cc normal saline 1 time dose

  Eligibility

Ages Eligible for Study:   14 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

-

Pregnant Women aged 14 years and over at ≥ 24 weeks' viable gestation who will undergo unscheduled/non-elective cesareans with either:

  1. Labor (spontaneous or induced): active labor (ongoing contractions and at least 4cm dilated or contractions for at least 4 hours with documented cervical change of ≥1cm dilatation or ≥50% effacement), or
  2. Membrane rupture (standardized to duration of at least 4 hours prior to randomization).

Exclusion Criteria:

  • Patient unwilling or unable to provide consent
  • Multiple pregnancy
  • Known azithromycin (or other macrolide) allergy
  • Vaginal delivery
  • Elective or scheduled cesarean prior to labor or membrane rupture.
  • Azithromycin, erythromycin or other macrolide antibiotic use within 7 days of enrollment.
  • Clinical chorioamnionitis or any other active bacterial infection (e.g. pyelonephritis, pneumonia, abscess) at time of randomization.
  • Patient is unable or unlikely to follow-up after delivery (e.g. no prenatal care or a non-resident patient)
  • Fetal demise or major congenital anomaly
  • Significant liver disease defined as known cirrhosis or elevated transaminases of at least 3-fold upper limit of normal
  • Significant renal disease defined as serum creatinine known to be >2.0 mg/dl or on dialysis.
  • Active congestive heart failure (EF<45%) or pulmonary edema
  • Active diarrhea at time of delivery
  • Any patient with significant electrolyte abnormalities such as hypokalemia or hypocalcemia
  • Any patient with structural heart disease or arrhythmias, or taking any medications known to prolong the QT interval
  • Patient currently being treated with efavirenz, nelfinavir or fluconazole
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01235546

Contacts
Contact: Alan TN Tita, MD, PhD 205-934-42565 alan.tita@obgyn.uab.edu
Contact: Rachel C LeDuke, MSN 205-934-5509 rcopper@uab.edu

Locations
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35233
Principal Investigator: Alan TN Tita, PhD, MD            
United States, North Carolina
University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27599-7516
Principal Investigator: Kim Boggess, MD            
United States, Texas
University of Texas Medical Branch Recruiting
Galveston, Texas, United States, 77555-0587
Principal Investigator: George Saade, MD            
Sponsors and Collaborators
Alan Tita
University of Texas
University of North Carolina
Investigators
Principal Investigator: Alan TN Tita, MD, PhD University of Alabama at Birmingham
  More Information

Publications:
Responsible Party: Alan Tita, Associate Professor, University of Alabama at Birmingham
ClinicalTrials.gov Identifier: NCT01235546     History of Changes
Other Study ID Numbers: F090323006, 1R01HD064729-01A1
Study First Received: November 4, 2010
Last Updated: March 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Alabama at Birmingham:
Pregnancy
Cesarean section
Antibiotic
Infections

Additional relevant MeSH terms:
Abscess
Endometritis
Wound Infection
Suppuration
Infection
Inflammation
Pathologic Processes
Pelvic Inflammatory Disease
Adnexal Diseases
Genital Diseases, Female
Uterine Diseases
Wounds and Injuries
Anti-Bacterial Agents
Azithromycin
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 16, 2013